181 results
424B3
PRTG
Portage Biotech Inc
6 Mar 24
Prospectus supplement
9:36pm
Forward - Looking Information This presentation contains forward - looking statements within the meaning of the United States Private Securities Litigation
6-K
EX-99.1
PRTG
Portage Biotech Inc
6 Mar 24
Current report (foreign)
9:11pm
- looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 . Statements in this presentation
6-K
EX-99.1
PRTG
Portage Biotech Inc
28 Feb 24
Company focused on adenosine platform clinical development
6:42pm
statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release
424B3
PRTG
Portage Biotech Inc
18 Jan 24
Prospectus supplement
5:41pm
Securities Litigation Reform Act of 1995 . Statements in this presentation that are not statements of historical fact are forward - looking statements
6-K
EX-99.1
PRTG
Portage Biotech Inc
18 Jan 24
Current report (foreign)
5:09pm
- looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 . Statements in this presentation
424B3
0spxz
7 Nov 23
Prospectus supplement
4:50pm
F-1
mdkgdq
31 Oct 23
Registration statement (foreign)
4:05pm
6-K
EX-10.1
0hxoi0xhg ik
3 Oct 23
Current report (foreign)
4:05pm
424B5
2ev72mu
2 Oct 23
Prospectus supplement for primary offering
6:01pm
424B5
gjtsucp
19 Aug 22
Prospectus supplement for primary offering
10:52am
6-K
EX-2.1
ypvkve28ol9on7 j3ixp
19 Jul 22
Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform
9:01am
6-K
EX-10.3
2s6m6lxjqtz
8 Jul 22
Current report (foreign)
8:58am
6-K
EX-10.4
7qqk5m
8 Jul 22
Current report (foreign)
8:58am
6-K
EX-2.1
k668ua2gl71ld
8 Jul 22
Current report (foreign)
8:58am
20-F/A
lk56de7
3 Mar 22
Annual report (foreign) (amended)
6:57pm